{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:47:03Z","timestamp":1777654023561,"version":"3.51.4"},"reference-count":133,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The rising prevalence of non-alcoholic fatty liver disease (NAFLD) parallels the global increase in the number of people diagnosed with obesity and metabolic syndrome. The gut-liver axis (GLA) plays an important role in the pathogenesis of NAFLD\/non-alcoholic steatohepatitis (NASH). In this review, we discuss the clinical significance and underlying mechanisms of action of gut-derived secretory factors in NAFLD\/NASH, focusing on recent human studies. Several studies have identified potential causal associations between gut-derived secretory factors and NAFLD\/NASH, as well as the underlying mechanisms. The effects of gut-derived hormone-associated drugs, such as glucagon-like peptide-1 analog and recombinant variant of fibroblast growth factor 19, and other new treatment strategies for NAFLD\/NASH have also been reported. A growing body of evidence highlights the role of GLA in the pathogenesis of NAFLD\/NASH. Larger and longitudinal studies as well as translational research are expected to provide additional insights into the role of gut-derived secretory factors in the pathogenesis of NAFLD\/NASH, possibly providing novel markers and therapeutic targets in patients with NAFLD\/NASH.<\/jats:p>","DOI":"10.3390\/ijms19103064","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T10:44:53Z","timestamp":1538995493000},"page":"3064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-9084","authenticated-orcid":false,"given":"Hirofumi","family":"Okubo","sequence":"first","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-7487","authenticated-orcid":false,"given":"Akifumi","family":"Kushiyama","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo 103-0002, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nakatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamamotoya","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuka","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Infection &amp; Inflammation, School of Medicine, Tulane University, 6823 St. Charles Avenue, New Orleans, LA 70118, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Fujishiro","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, Tokyo 173-8610, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Sakoda","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruya","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayasu","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine for Diabetes and Lifestyle-related Diseases, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoichiro","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"673","article-title":"NASH: A glance at the landscape of pharmacological treatment","volume":"15","author":"Brodosi","year":"2016","journal-title":"Ann. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.cellbio.042308.113344","article-title":"Vertebrate endoderm development and organ formation","volume":"25","author":"Zorn","year":"2009","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15518","DOI":"10.3748\/wjg.v20.i42.15518","article-title":"Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease","volume":"20","author":"Paolella","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20157","DOI":"10.1038\/srep20157","article-title":"Involvement of resistin-like molecule beta in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice","volume":"6","author":"Okubo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.gastro.2003.07.009","article-title":"Bacterial colonization leads to the colonic secretion of RELMbeta\/FIZZ2, a novel goblet cell-specific protein","volume":"125","author":"He","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/ATVBAHA.113.301546","article-title":"Resistin-like molecule beta is abundantly expressed in foam cells and is involved in atherosclerosis development","volume":"33","author":"Kushiyama","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00125-005-1735-1","article-title":"Serum concentrations of resistin-like molecules beta and gamma are elevated in high-fat-fed and obese db\/db mice, with increased production in the intestinal tract and bone marrow","volume":"48","author":"Shojima","year":"2005","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.febslet.2006.01.012","article-title":"Human RELMbeta is a mitogenic factor in lung cells and induced in hypoxia","volume":"580","author":"Renigunta","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1073\/pnas.98.2.502","article-title":"A family of tissue-specific resistin-like molecules","volume":"98","author":"Steppan","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.1073\/pnas.1711395114","article-title":"Resistin-like molecule beta is a bactericidal protein that promotes spatial segregation of the microbiota and the colonic epithelium","volume":"114","author":"Propheter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13596","DOI":"10.1053\/j.gastro.2009.08.042","article-title":"High-fat diet determines the composition of the murine gut microbiome independently of obesity","volume":"137","author":"Hildebrandt","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13596","DOI":"10.1073\/pnas.0404034101","article-title":"RELMbeta\/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract","volume":"101","author":"Artis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1084\/jem.20091268","article-title":"Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection","volume":"206","author":"Herbert","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.4049\/jimmunol.179.10.7012","article-title":"Resistin-like molecule beta (RELMbeta\/FIZZ2) is highly expressed in the ileum of SAMP1\/YitFc mice and is associated with initiation of ileitis","volume":"179","author":"Barnes","year":"2007","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bergstrom, K.S., Morampudi, V., Chan, J.M., Bhinder, G., Lau, J., Yang, H., Ma, C., Huang, T., Ryz, N., and Sham, H.P. (2015). Goblet Cell Derived RELM-beta Recruits CD4+ T Cells during Infectious Colitis to Promote Protective Intestinal Epithelial Cell Proliferation. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005108"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI28121","article-title":"Absence of bacterially induced RELMbeta reduces injury in the dextran sodium sulfate model of colitis","volume":"116","author":"McVay","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.4049\/jimmunol.181.7.4709","article-title":"Goblet cell-derived resistin-like molecule beta augments CD4+ T cell production of IFN-gamma and infection-induced intestinal inflammation","volume":"181","author":"Nair","year":"2008","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chellappa, K., Deol, P., Evans, J.R., Vuong, L.M., Chen, G., Briancon, N., Bolotin, E., Lytle, C., Nair, M.G., and Sladek, F.M. (2016). Opposing roles of nuclear receptor HNF4alpha isoforms in colitis and colitis-associated colon cancer. Elife, 5.","DOI":"10.7554\/eLife.10903"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/mi.2015.140","article-title":"The goblet cell-derived mediator RELM-beta drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis","volume":"9","author":"Morampudi","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kitade, H., Chen, G., Ni, Y., and Ota, T. (2017). Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 9.","DOI":"10.3390\/nu9040387"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1172\/JCI16521","article-title":"Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production","volume":"111","author":"Rajala","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"42016","DOI":"10.1074\/jbc.M503065200","article-title":"Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet","volume":"280","author":"Kushiyama","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000079152","article-title":"Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells","volume":"69","author":"Montalto","year":"2004","journal-title":"Digestion"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/nu3010104","article-title":"Effect of lactobacilli on paracellular permeability in the gut","volume":"3","author":"Ahrne","year":"2011","journal-title":"Nutrients"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"G911","DOI":"10.1152\/ajpgi.00225.2013","article-title":"Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model","volume":"305","author":"Okubo","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2006.04.039","article-title":"Resistin-like molecule beta regulates innate colonic function: Barrier integrity and inflammation susceptibility","volume":"118","author":"Hogan","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.canep.2010.10.007","article-title":"Plasma levels of resistin-like molecule beta in humans","volume":"35","author":"Neilson","year":"2011","journal-title":"Cancer Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0165-6147(03)00160-3","article-title":"The glucagon-like peptides: A double-edged therapeutic sword?","volume":"24","author":"Perry","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","article-title":"Incretin-based therapy: A powerful and promising weapon in the treatment of type 2 diabetes mellitus","volume":"2","author":"Koliaki","year":"2011","journal-title":"Diabetes Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1210\/jc.2008-1296","article-title":"Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides","volume":"94","author":"Rabiee","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cea.12860","article-title":"Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation","volume":"47","author":"Mitchell","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Zvibel","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-Acting Glucagon-Like Peptide 1 Receptor Agonists A review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bernsmeier, C., Meyer-Gerspach, A.C., Blaser, L.S., Jeker, L., Steinert, R.E., Heim, M.H., and Beglinger, C. (2014). Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087488"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cuthbertson, D.J., Irwin, A., Gardner, C.J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E.L., Adams, V.L., and Pushpakom, S.P. (2012). Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050117"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of Oral Semaglutide Compared with Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients with Type 2 Diabetes: A Randomized Clinical Trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cmet.2017.04.013","article-title":"A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism","volume":"25","author":"Grasset","year":"2017","journal-title":"Cell Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2174\/0929867324666171009121702","article-title":"Gut Microbiota as a Therapeutic Target for Metabolic Disorders","volume":"25","author":"Okubo","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Ann. Rev. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/en.2003-0801","article-title":"Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1","volume":"145","author":"Ugleholdt","year":"2004","journal-title":"Endocrinology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0016-5085(99)70555-X","article-title":"Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans","volume":"117","author":"Xiao","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_59","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J. Clin. Endocr. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MCO.0b013e32832d23cd","article-title":"Short bowel syndrome: The role of GLP-2 on improving outcome","volume":"12","author":"Wallis","year":"2009","journal-title":"Curr. Opin. Clin. Nutr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1073\/pnas.96.4.1569","article-title":"Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2","volume":"96","author":"Munroe","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E460","DOI":"10.1152\/ajpendo.00149.2007","article-title":"Frontiers in glucagon-like peptide-2: Multiple actions, multiple mediators","volume":"293","author":"Dube","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1210\/en.2006-1232","article-title":"Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat","volume":"148","author":"Nelson","year":"2007","journal-title":"Endocrinology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.numecd.2010.07.014","article-title":"Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart","volume":"22","author":"Angelone","year":"2012","journal-title":"Nutr. Metab. Cardiovasc. Dis. NMCD"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"G274","DOI":"10.1152\/ajpgi.00389.2012","article-title":"Glugacon-like peptide-2: Broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration","volume":"307","author":"Erdual","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/77535","article-title":"The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake","volume":"6","author":"Larsen","year":"2000","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.ijo.0802247","article-title":"No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects","volume":"27","author":"Sorensen","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1152\/ajpendo.1997.273.1.E77","article-title":"Intestinal growth-promoting properties of glucagon-like peptide-2 in mice","volume":"273","author":"Tsai","year":"1997","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"G964","DOI":"10.1152\/ajpgi.00509.2003","article-title":"Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome","volume":"286","author":"Martin","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/j.gastro.2012.09.007","article-title":"Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure","volume":"143","author":"Jeppesen","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/bj20020393","article-title":"Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2","volume":"367","author":"Au","year":"2002","journal-title":"Biochem. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10620-004-9561-8","article-title":"Effect of glucagon-like peptide-2 (GLP-2) on diurnal SGLT1 expression","volume":"49","author":"Ramsanahie","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1203\/00006450-200210000-00007","article-title":"Glucagon-Like Peptide 2 Enhances Maltase-Glucoamylase and Sucrase-Isomaltase Gene Expression and Activity in Parenterally Fed Premature Neonatal Piglets","volume":"52","author":"Petersen","year":"2002","journal-title":"Pediatr. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","article-title":"Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans","volume":"130","author":"Meier","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2014.08.037","article-title":"Glucagon-like peptide-2 regulates release of chylomicrons from the intestine","volume":"147","author":"Dash","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gut.47.1.112","article-title":"Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse","volume":"47","author":"Benjamin","year":"2000","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.regpep.2012.07.002","article-title":"GLP-2 enhances barrier formation and attenuates TNFalpha-induced changes in a Caco-2 cell model of the intestinal barrier","volume":"178","author":"Moran","year":"2012","journal-title":"Regul. Pept."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MCG.0b013e3181e12c24","article-title":"Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis","volume":"45","author":"Verdam","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.161497","article-title":"GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus","volume":"333","author":"Moore","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"G800","DOI":"10.1152\/ajpgi.00170.2009","article-title":"Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro","volume":"297","author":"Baldassano","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/07435800.2016.1141950","article-title":"Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet","volume":"41","author":"Baldassano","year":"2016","journal-title":"Endocr. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1210\/jc.2013-1308","article-title":"Feeding and bone turnover in gastric bypass","volume":"99","author":"Valderas","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13098-015-0006-7","article-title":"The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitus","volume":"7","author":"Lopes","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2036.2006.03193.x","article-title":"Review article: Glucagon-like peptide 2--current applications and future directions","volume":"25","author":"Wallis","year":"2007","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1074\/jbc.M110.116004","article-title":"Regulation of bile acid synthesis by fat-soluble vitamins A and D","volume":"285","author":"Schmidt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1194\/jlr.M012781","article-title":"A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB\/NJ mice","volume":"52","author":"Henkel","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"15482","DOI":"10.1074\/jbc.275.20.15482","article-title":"Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4","volume":"275","author":"Yu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho","volume":"115","author":"Ito","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.0913986107","article-title":"Relevant use of Klotho in FGF19 subfamily signaling system in vivo","volume":"107","author":"Tomiyama","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Wu, A.L., Coulter, S., Liddle, C., Wong, A., Eastham-Anderson, J., French, D.M., Peterson, A.S., and Sonoda, J. (2011). FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017868"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: From feast to famine","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molmet.2013.10.002","article-title":"Central action of FGF19 reduces hypothalamic AGRP\/NPY neuron activity and improves glucose metabolism","volume":"3","author":"Marcelin","year":"2014","journal-title":"Mol. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/en.2012-1891","article-title":"Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats","volume":"154","author":"Ryan","year":"2013","journal-title":"Endocrinology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1203\/00006450-200104000-00014","article-title":"Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids","volume":"49","author":"Sokol","year":"2001","journal-title":"Pediatr. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3164\/jcbn.13-46","article-title":"The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury","volume":"54","author":"Adachi","year":"2014","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"Aranha","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1515\/jpem-2012-0253","article-title":"A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents","volume":"25","author":"Wojcik","year":"2012","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Alisi, A., Ceccarelli, S., Panera, N., Prono, F., Petrini, S., De Stefanis, C., Pezzullo, M., Tozzi, A., Villani, A., and Bedogni, G. (2013). Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067160"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A Mouse Model of Hepatocellular Carcinoma","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Miura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., and Miyazaki, M. (2012). Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-56"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1158\/0008-5472.CAN-07-2325","article-title":"Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling","volume":"68","author":"Pai","year":"2008","journal-title":"Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"French, D.M., Lin, B.C., Wang, M., Adams, C., Shek, T., Hotzel, K., Bolon, B., Ferrando, R., Blackmore, C., and Schroeder, K. (2012). Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036713"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/270183a0","article-title":"Specific localisation of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry","volume":"270","author":"Polak","year":"1977","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","article-title":"Neurotensin and neurotensin receptors","volume":"20","author":"Vincent","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.regpep.2011.04.005","article-title":"Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function","volume":"170","author":"Kalafatakis","year":"2011","journal-title":"Regul. Pept."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0196-9781(81)90042-5","article-title":"Elevation of plasma neurotensin during lipid perfusion of rat small intestine","volume":"2","author":"Ferris","year":"1981","journal-title":"Peptides"},{"key":"ref_124","first-page":"G823","article-title":"Neurotensin stimulates [3H]oleic acid translocation across rat small intestine","volume":"251","author":"Armstrong","year":"1986","journal-title":"Am. J. Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/00365528809093893","article-title":"Local Effect of Neurotensin on Canine Ileal Blood-Flow, and Its Release by Luminal Lipid","volume":"23","author":"Hammer","year":"1988","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00006676-198805000-00015","article-title":"Effect of Neurotensin on Pancreatic and Gastric-Secretion and Growth in Rats","volume":"3","author":"Wood","year":"1988","journal-title":"Pancreas"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1210\/en.2017-00122","article-title":"Loss of Action via Neurotensin-Leptin Receptor Neurons Disrupts Leptin and Ghrelin-Mediated Control of Energy Balance","volume":"158","author":"Brown","year":"2017","journal-title":"Endocrinology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2012.12998","article-title":"Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality","volume":"308","author":"Melander","year":"2012","journal-title":"JAMA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nature17662","article-title":"An obligatory role for neurotensin in high-fat-diet-induced obesity","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1210\/jc.2017-02751","article-title":"Increased Plasma Proneurotensin Levels Identify NAFLD in Adults with and Without Type 2 Diabetes","volume":"103","author":"Barchetta","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Barchetta, I., Cimini, F.A., Capoccia, D., Bertoccini, L., Ceccarelli, V., Chiappetta, C., Leonetti, F., Di Cristofano, C., Silecchia, G., and Orho-Melander, M. (2018). Neurotensin Is a Lipid-Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. Nutrients, 10.","DOI":"10.3390\/nu10040526"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/oby.22058","article-title":"Low Circulating Levels of Neurotensin in Women with Nonalcoholic Fatty Liver Disease Associated with Severe Obesity","volume":"26","author":"Auguet","year":"2018","journal-title":"Obesity"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.peptides.2006.01.021","article-title":"Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation","volume":"27","author":"Ernst","year":"2006","journal-title":"Peptides"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:24:21Z","timestamp":1760196261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":133,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["ijms19103064"],"URL":"https:\/\/doi.org\/10.3390\/ijms19103064","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]}}}